Cargando…

A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance

Clinical efficacy of oxaliplatin is frequently limited by severe adverse effects and therapy resistance. Acquired insensitivity to oxaliplatin is, at least in part, associated with elevated levels of glutathione (GSH). In this study we report on an oxaliplatin-based platinum(IV) prodrug, which relea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fronik, Philipp, Gutmann, Michael, Vician, Petra, Stojanovic, Mirjana, Kastner, Alexander, Heffeter, Petra, Pirker, Christine, Keppler, Bernhard K., Berger, Walter, Kowol, Christian R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814792/ https://www.ncbi.nlm.nih.gov/pubmed/36697790 http://dx.doi.org/10.1038/s42004-022-00661-z

Ejemplares similares

Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs
por: Kastner, Alexander, et al.
Publicado: (2023)

Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands
por: Fronik, Philipp, et al.
Publicado: (2021)

Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo
por: Schueffl, Hemma, et al.
Publicado: (2021)

Development of a cobalt(iii)-based ponatinib prodrug system
por: Mathuber, Marlene, et al.
Publicado: (2021)

An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo
por: Mayr, Josef, et al.
Publicado: (2017)

EGFR-targeting peptide-coupled platinum(IV) complexes
por: Mayr, Josef, et al.
Publicado: (2017)

Loss of phosphodiesterase 4D mediates acquired triapine resistance via Epac-Rap1-Integrin signaling
por: Miklos, Walter, et al.
Publicado: (2016)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
por: Bielec, Bjoern, et al.
Publicado: (2020)

Synthesis, Characterization and in vitro Studies of a Cathepsin B‐Cleavable Prodrug of the VEGFR Inhibitor Sunitinib
por: Karnthaler‐Benbakka, Claudia, et al.
Publicado: (2018)

Landomycins as glutathione-depleting agents and natural fluorescent probes for cellular Michael adduct-dependent quinone metabolism
por: Terenzi, Alessio, et al.
Publicado: (2021)

Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs
por: Mathuber, Marlene, et al.
Publicado: (2020)

A Dogma in Doubt: Hydrolysis of Equatorial Ligands of Pt(IV) Complexes under Physiological Conditions
por: Kastner, Alexander, et al.
Publicado: (2019)

Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment?
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands
por: Mendrina, Theresa, et al.
Publicado: (2023)

Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance
por: Papadia, Paride, et al.
Publicado: (2020)

Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney
por: Legin, A. A., et al.
Publicado: (2016)

Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones
por: Heffeter, Petra, et al.
Publicado: (2012)

Glutathione boosting the cytotoxicity of a magnetic platinum(iv) nano-prodrug in tumor cells
por: Zhu, Zhenzhu, et al.
Publicado: (2016)

Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance
por: Pósa, Vivien, et al.
Publicado: (2022)

Oxaliplatin-Based Platinum(IV) Prodrug Bearing Toll-like Receptor 7 Agonist for Enhanced Immunochemotherapy
por: Tang, Li, et al.
Publicado: (2019)

Liposomal formulations of anticancer copper(ii) thiosemicarbazone complexes
por: Mathuber, Marlene, et al.
Publicado: (2021)

Potent Chlorambucil-Platinum(IV) Prodrugs
por: Aputen, Angelico D., et al.
Publicado: (2022)

Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux
por: Bormio Nunes, Julia H., et al.
Publicado: (2020)

The impact of whole human blood on the kinetic inertness of platinum(iv) prodrugs – an HPLC-ICP-MS study
por: Theiner, Sarah, et al.
Publicado: (2018)

Behavior of platinum(iv) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation†
por: Schreiber-Brynzak, Ekaterina, et al.
Publicado: (2016)

Structure elucidation and quantification of the reduction products of anticancer Pt(iv) prodrugs by electrochemistry/mass spectrometry (EC-MS)
por: Frensemeier, L. M., et al.
Publicado: (2018)

Ligand Evolution in the Photoactivatable Platinum(IV) Anticancer Prodrugs
por: Huang, Jingjing, et al.
Publicado: (2022)

Repurposing Platinum(IV) Prodrugs to Modulate Mitochondrial Metabolism
por: Zacharioudakis, Emmanouil, et al.
Publicado: (2023)

Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones
por: Pelivan, Karla, et al.
Publicado: (2018)

Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity
por: Khoury, Aleen, et al.
Publicado: (2022)

Cell-permeable lanthanide–platinum(iv) anti-cancer prodrugs
por: Yao, Kezi, et al.
Publicado: (2021)

Biological activity of Pt(IV) prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis
por: Alonso-de Castro, Silvia, et al.
Publicado: (2018)

Osmium(IV) complexes with 1H- and 2H-indazoles: Tautomer identity versus spectroscopic properties and antiproliferative activity
por: Büchel, Gabriel E., et al.
Publicado: (2012)

Copper-Catalyzed Glutathione Oxidation is Accelerated by the Anticancer Thiosemicarbazone Dp44mT and Further Boosted at Lower pH
por: Falcone, Enrico, et al.
Publicado: (2022)

Platinum(IV)-Loaded Degraded Glycol Chitosan as Efficient Platinum(IV) Drug Delivery Platform
por: Lerchbammer-Kreith, Yvonne, et al.
Publicado: (2023)

Impact of Stepwise NH(2)-Methylation of Triapine on the Physicochemical Properties, Anticancer Activity, and Resistance Circumvention
por: Kowol, Christian R., et al.
Publicado: (2016)

Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs
por: Wong, Daniel Yuan Qiang, et al.
Publicado: (2015)

Versatile Platinum(IV) Prodrugs of Naproxen and Acemetacin as Chemo-Anti-Inflammatory Agents
por: Aputen, Angelico D., et al.
Publicado: (2023)

Self-assembly nanoplatform of platinum (Ⅳ) prodrug for enhanced ovarian cancer therapy
por: Ma, Xiao, et al.
Publicado: (2023)

NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer
por: Trondl, Robert, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j3a4au13043mumh4hgar228rs5